Interleukin-6, tumor necrosis factor-α, and CD5 immunolabeling of new experimental endodontic sealer and repair material

Autor: Francine Benetti, Luciana Louzada Ferreira, Alexandre Henrique Dos Reis-Prado, Flávio Duarte Faria, Edilson Ervolino, Fabio Luiz Camargo Vellela Berbert, Renato de Toledo Leonardo, João Dias, João Eduardo Gomes-Filho, Luciano Tavares Angelo Cintra
Rok vydání: 2022
Předmět:
Zdroj: Odontology. 111:93-104
ISSN: 1618-1255
1618-1247
DOI: 10.1007/s10266-022-00723-7
Popis: The aim of this study was to evaluate the biocompatibility and immunoinflammatory response of the Sealepox and Sealepox-RP, based on interleukin (IL)-6, tumor necrosis factor (TNF)-α, and CD5 immunolabelling. The ProRoot MTA (PRMTA) was used for comparison. Polyethylene tubes (1.0-mm internal, 1.6-mm external diameter, and 10.0-mm length; ISO 10993) with or without (control) materials were randomly implanted in the dorsum of 35 rats (4 per rat). After 7, 15, 30, 60, and 90 days (n = 7), the tubes were removed for histological and immunohistochemical analysis. The Kruskal-Wallis and Dunn's test for non-parametric data and, ANOVA and Tukey test for parametric data were used (P 0.05). Hematoxylin and eosin staining revealed that the concentration of inflammatory cells decreased over time with no differences between groups in all periods (P 0.05). Regarding IL-6 immunostaining, there was no difference at 7 days (P 0.05); all groups decreased over time, being faster for the PRMTA group and also, with no differences between groups in the last period (P 0.05). For TNF-α, at 7 days there was no difference between groups (P 0.05); there was an increase at 15 days for PRMTA and, at 30 and 60 days, for PRMTA and Sealepox compared to the control (P 0.05). At 90 days, Sealepox RP showed the lowest immunostaining being similar to the control (P 0.05). Regarding CD5 cells, at 7 days, there was high immunostaining for PRMTA compared to the control (P 0.05); and significant reduction over time with difference for all groups at 30 and 60 days. (P 0.05); Sealepox was similar to the control in all periods (P 0.05). Sealepox RP showed the highest immunostaining at 15 days, being different from the control and PRMTA (P 0.05); in the other periods it was similar to the control (P 0.05). It can be concluded that Sealepox and Sealepox-RP were biocompatible and demonstrated similar immunoinflammatory response regarding IL-6, TNF-α, and CD5 compared to PRMTA.
Databáze: OpenAIRE
Externí odkaz: